Company intelligence / Profile preview

Chongqing Sintaho Pharmaceutical

Chongqing, Chongqing, China

Ownership: Private
Employees: ~260
Development stage: Other

Overview

Sintaho is an established supplier of GMP-compliant cytotoxic and non-cytotoxic APIs including docetaxel, paclitaxel, carfilzomib, tirbanibulin, and eribulin, with approvals and DMFs in >30 countries including China, US, EU. Clinical results for these molecules are referenced for approved/marketed products only, not for Sintaho-specific clinical development.

Therapeutic areas: OncologyNeurologyMetabolic Disorders
Modalities: Small moleculePolypeptideAntibody-drug conjugate (ADC)
Industry: Contract Manufacturing Organization

Partnerships

Not explicitly listed; extensive partnerships reported with global pharma companies for supply chain/API production. Linked in global supply chain network, serving US, EU, China, etc.

Beyond the preview

Go deeper on Chongqing Sintaho Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chongqing Sintaho Pharmaceutical.

Explore the full profile